|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Potential beneficial effects of butyrate in intestinal and extraintestinal diseases显示文摘The multiple beneficial effects on human health of the short-chain fatty acid butyrate,synthesized from nonabsorbed carbohydrate by colonic microbiota,are well documented.At the intestinal level,butyrate plays a regulatory role on the transepithelial fluid transport,ameliorates mucosal inflammation and oxidative status,reinforces the epithelial defense barrier,and modulates visceral sensitivity and intestinal motility.In addition,a growing number of studies have stressed the role of butyrate in the prevention and inhibition of colorectal cancer.At the extraintestinal level,butyrate exerts potentially useful effects on many conditions,including hemoglobinopathies,genetic metabolic diseases,hypercholesterolemia,insulin resistance,and ischemic stroke.The mechanisms of action of butyrate are different;many of these are related to its potent regulatory effects on gene expression.These data suggest a wide spectrum of positive effects exerted by butyrate,with a high potential for a therapeutic use in human medicine. | Roberto Berni Canani Margherita Di Costanzo Ludovica Leone Monica Pedata Rosaria Meli Antonio Calignano | 2011 | World Journal of Gastroenterology2011，17，12： | 52 |
| 2 | Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives显示文摘During the last two decades, various local thermal ablative techniques for the treatment of unresectable hepatocellular carcinoma(HCC) have been developed. According to internationally endorsed guidelines, percutaneous thermal ablation is the mainstay of treatment in patients with small HCC who are not candidates for surgical resection or transplantation. Laser ablation(LA) represents one of currently available loco-ablative techniques. In this article, the general principles, technique, image guidance, and patient selection are reported. Primary effectiveness, long-term outcome, and complications are also discussed. A review of published data suggests that LA is equivalent to the more popular and widespread radiofrequency ablation in both local tumor control and long-term outcome in the percutaneous treatment of early HCC. In addition, the LA technique using multiple thin laser fibres allows improved ablative effectiveness in HCCs greater than 3 cm. Reference centres should be equipped with all the available techniques so as to be able to use the best and the most suitable procedure for each type of lesion for each patient. | Giovan Giuseppe Di Costanzo Giampiero Francica Claudio Maurizio Pacella | 2014 | World Journal of Hepatology2014，6，10： | 14 |
| 3 | Intermediate hepatocellular carcinoma: How to choose the best treatment modality?显示文摘Intermediate stage, or stage B according to Barcelona Clinic Liver Cancer classification, of hepatocellular carcinoma(HCC) comprises a heterogeneous population with different tumor burden and liver function. This heterogeneity is confirmed by the large variability of treatment choice and disease-relate survival. The aim of this review was to highlight the existing evidences regarding this specific topic. In a multidisciplinary evaluation, patients with large(> 5 cm) solitary HCC should be firstly considered for liver resection(LR). When LR is unfeasible, locoregional treatments are evaluable therapeutic options, being transarterial chemoembolization(TACE), the most used procedure. Percutaneous ablation can be an evaluable treatment for large HCC. However, the efficacy of all ablative procedures decrease as tumor size increases over 3 cm. In clinical practice, a combination treatment strategy [TACE or transarterial radioembolization(TARE)-plus percutaneous ablation] is 'a priori' preferred in a relevant percentage of these patients. On the other hands, sorafenib is the treatment of choice in patients who are unsuitable to surgery and/or with a contraindication to locoregional treatments. In multifocal HCC, TACE is the first-line treatment. The role of TARE is still undefined. Surgery may have also a role in the treatment of multifocal HCC in selected cases(patients with up to three nodules, multifocal HCC involving 2-3 adjacent liver segments). In some patients with bilobar disease the combination of LR and ablative treatment may be a valuable option. The choice of the best treatment in the patient with intermediate stage HCC should be 'patient-tailored' and made by a multidisciplinary team. | Giovan Giuseppe Di Costanzo Raffaella Tortora | 2015 | World Journal of Hepatology2015，7，9： | 12 |
| 4 | 酒精摄入、心脏生物标志物和心房颤动风险与不良结局显示文摘酒精摄入和新发心房颤动相关性证据不一,尤其是在低剂量下。该研究评估欧洲队列在整个饮酒范围内酒精摄入、生物标志物和新发心房颤动的关系。方法和结果:在一个以社区为基础的汇集队列中,研究者随访107845人,以评估酒精摄入(酒精种类和饮酒方式)与新发心房颤动的关系。研究者收集经典心血管病危险因素和新发心力衰竭的信息,并检测生物标记物氨基末端脑钠肽前体和高敏肌钙蛋白I。 | 陈嘉睿(译) 练桂丽((审校) Csengeri D Sprünker NA Di Castelnuovo A Niiranen T Vishram-Nielsen JK Costanzo S S derberg S Jensen SM Vartiainen E Donati MB Magnussen C Camen S Gianfagna F L chen ML Kee F Kontto J Mathiesen EB Koenig W Stefan B de Gaetano G J rgensen T Kuulasmaa K Zeller T Salomaa V Iacoviello L Schnabel RB | 2021 | 中华高血压杂志2021，29，2： | 9 |
| 5 | 脑胶质瘤的3 T质子MRS分析:空间分布、肿瘤级别和范围显示文摘本研究旨在评价3T质子MR波谱成像(^1H—MRS)在鉴别高低级别胶质瘤、肿瘤与坏死、水肿和正常组织中的作用。复习了44例脑胶质瘤和4例脑膜瘤病人的MR资料。计算标准化后的代谢物浓度[胆碱(nCho)、N-乙酰天门冬氨酸(nNAA)、肌酸(nCr)和乳酸/月旨质(nLL)]以及代谢物浓度比值(Cho/NAA、NAA/Cr和Cho/Cr)。影像表现为坏死的区域显示出2种波谱形式:含有一定nCho和高nLL的“坏死”,含有一定nLL或无明显代谢峰值的“囊状坏死”。 | A.Di Costanzo T. Scarabino F. Trojsi T. Popolizio D. Catapano G.M.Giannatempo 郭雪梅(译) 唐光健(校) | 2008 | 国际医学放射学杂志2008，31，5： | 5 |
| 6 | Decrease of serum carnitine levels in patients with or without gastrointestinal cancer cachexia显示文摘瞄准:在消化机关与癌症在病人评估浆液肉毒碱的层次并且把他们与另外的癌症作比较以便提供新卓见进极度瘦弱的机制。方法:55 个恶病质病人与或没有胃肠的癌症在现在的学习被注册。他们经历了平淡的实验室调查,包括在浆液在场的肉毒碱的各种各样的形式的层次的检查(即,长链的酰肉毒碱,短链的酰肉毒碱,免费肉毒碱,和全部的肉毒碱) 。这些价值与 30 个健康控制题目在好营养的地位以及与那些在 60 个癌症病人发现的那些相比。结果:当没有胃肠的癌症,有胃肠的癌症的恶病质病人与恶病质病人相比时,差别是在免费肉毒碱的 -6.8 micromol/L (P <
0.005 ) ,在长链酰肉毒碱的 0.04 micromol/L (P <
0.05 ) ,在全部的肉毒碱的 8.7 micromol/L (P <
0.001 ) 。在恶病质病人与或没有胃肠的癌症,差别是在免费肉毒碱的 12.2 micromol/L ( P <
0.001 ),在短链酰肉毒碱的 4.60 micromol/L ( P <
0.001 ),并且在长链的酰肉毒碱的 0.60 微摩尔 /L ( P <
0.005 )并且在全部的肉毒碱的 17.4 micromol/L ( P <
0.001 )。在有胃肠的癌症和健康控制题目的恶病质病人,差别是在免费肉毒碱的 15.5 micromol/L ( P <
0.001 ),在短链的酰肉毒碱的 5.2 微摩尔 /L ( P <
0.001 ),在长链酰肉毒碱的 1.0 micromol/L ( P <
0.001 ),并且在全部的肉毒碱的 21.8 micromol/L ( P <
0.001 )。结论:在终端的肉毒碱的低浆液层次肿瘤的病人由于减少的饮食的吸入极大地被减少并且损害了这种物质的内长的合成。这些低浆液肉毒碱层次也在癌症病人贡献极度瘦弱的前进。 | Mariano Malaguarnera Corrado Risino Maria Pia Gargante Giovanni Oreste Gloria Barone Anna Veronica Tomasello Mario Costanzo Matteo Angelo Cannizzaro | 2006 | World Journal of Gastroenterology2006，12，28： | 3 |
| 7 | Removal of antibiotics in conventional and advanced wastewater treatment: Implications for environmental discharge and wastewater recycling显示文摘 | A.J. Watkinson E.J. Murby S.D. Costanzo | 2007 | Water Research2007，，18： | 2 |
| 8 | Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice显示文摘 | Giovan Giuseppe Di Costanzo Raffaella Tortora Luca Iodice Alfonso Galeota Lanza Filippo Lampasi Maria Teresa Tartaglione Francesco Paolo Picciotto Silvana Mattera Massimo De Luca | 2012 | Digestive and Liver Disease2012，，9： | 2 |
| 9 | Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)显示文摘 | Kirkwood F. Adams Gregg C. Fonarow Charles L. Emerman Thierry H. LeJemtel Maria Rosa Costanzo William T. Abraham Robert L. Berkowitz Marie Galvao Darlene P. Horton | 2005 | American Heart Journal2005，，2： | 2 |
| 10 | HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient显示文摘 | Nicola Coppola Giovanna Loquercio Gilda Tonziello Rosa Azzaro Mariantonietta Pisaturo Gaetano Di Costanzo Mario Starace Giuseppe Pasquale Carmela Cacciapuoti Arnolfo Petruzziello | 2013 | Journal of Clinical Virology2013，，： | 2 |
| 11 | Ultrafiltration Versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure显示文摘 | Maria Rosa Costanzo Maya E. Guglin Mitchell T. Saltzberg Mariell L. Jessup Bradley A. Bart John R. Teerlink Brian E. Jaski James C. Fang Erika D. Feller Garrie J. Haas Allen S. Anderson Michael P. Schollmeyer Paul A. Sobotka | 2007 | Journal of the American College of Cardiology2007，，6： | 2 |
| 12 | 肥胖与急性心力衰竭的矛盾关系——关于体重指数与急性失代偿心力衰竭患者院内死亡率的分析显示文摘 | Fonarow GC Srikanthan P Costanzo MR 蒋晖(摘译) | 2007 | 心血管病学进展2007，28，4： | 2 |
| 13 | In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications显示文摘 | William T. Abraham Kirkwood F. Adams Gregg C. Fonarow Maria Rosa Costanzo Robert L. Berkowitz Thierry H. LeJemtel Mei L. Cheng Janet Wynne | 2005 | Journal of the American College of Cardiology2005，，： | 2 |
| 14 | UCP2 inhibition triggers ROS-dependent nuclear translocation of GAPDH and autophagic cell death in pancreatic adenocarcinoma cells显示文摘 | Ilaria Dando Claudia Fiorini Elisa Dalla Pozza Chiara Padroni Chiara Costanzo Marta Palmieri Massimo Donadelli | 2013 | BBA - Molecular Cell Research2013，，3： | 2 |
| 15 | Early initiation of intravenous vasoactive therapy improves heart failure outeomes:an analysis from the ADHERE registry database显示文摘 | Peacock F Emerman C Costanzo M | 2003 | Ann Emerg Med2003，42，4： | 1 |
| 16 | Phase Ⅱ study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours 显示文摘 | Caraglia M Addeo R Costanzo R | 2006 | Cancer Chemother Phannacol2006，57，1： | 1 |
| 17 | Uhrafihratiou versus intravenous diuretics for patients hospitalized for acute decompensated heart failure 显示文摘 | Costanzo MR Guglin ME Saltzberg MT | 2007 | J Am Coll Cardiol2007，49，： | 1 |
| 18 | Structure,fhnc- tion and regulation of p63 and p73显示文摘 | Levrero M Laurenzi VD Costanzo A | 1999 | Ce 11 death and Def- ferenfiafion1999，6，12： | 1 |
| 19 | Single seed viability checked by delayed luminescence显示文摘 | Costanzo E Gulino M Lanzano L | 2008 | European Biophysies Journal2008，37，2： | 1 |
| 20 | Evolutionary dynamics of the genomic region around the blast resistance gene Pi-ta in AA genome Oryza species显示文摘 | LEE S COSTANZO S JIA Y | 2009 | Genetics2009，183，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员